Market Overview

Celgene Shares Have Pulled Back, But Is It Enough?

Share:
Related CELG
Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
Stocks Quietly Mixed In Afternoon; Skyworks Breaks Out, Celgene Bases (Investor's Business Daily)

Celgene Corporation (NASDAQ: CELG) has rewarded shareholders for their optimism and patience with a run from the 2009 low of around $20 to the recent peak near $130.

Nothing grows straight up forever, though, and a little pullback in Celgene shares has taken place in recent days.

How much more of a pullback is warranted, though?

What The Bulls See

  • Net profit margins of 26.07 percent that spin off over $2.06 billion in positive levered free cash flow annually
    • Return on assets of 10.97 percent
    • Return on equity of 33.02 percent
  • $7.55 billion in cash versus total debt of $6.88 billion
  • Current ratio of 4.6
  • A reasonable PE of around 19 versus estimated revenue and earnings growth of 21.7 percent and 31.3 percent, respectively
  • Related Link: 3 Biotech Stocks Bucking Short-Interest Trends

    What The Bears See

    • A debt-to-equity ratio of 105.37 percent
    • A market capitalization of $95.01 billion that exceeds the market capitalization of $94.34 billion
    • A price-to-sales ratio of 12.28
    • A price-to-book ratio of 14.43

    The Technical Take

    Technicians note that Celgene shares are declining after testing the upper edge of the intermediate-term uptrend channel at around $129 recently (the resistance created by that line would now come in at $132 - $133). They have come down off that resistance and successfully held initial horizontal line support at $113.67.

    Should that level of support fail, the next test for Celgene would be the lower edge of the intermediate-term uptrend channel at around $104, which would also correspond with horizontal line support created by the November and December intra-month lows.

    Overall

    Celgene is very pricey by some metrics and not so pricey based on P/E ratios. The company is great fundamentally, so any rich valuations may be well-deserved.

    Any misstep by management, however, would be a trigger for significant selling pressure. Unless and until that happens, Celgene shares will likely be accumulated on dips to support.

    Stock chart: 
    Stock chart

    Posted-In: Biotech Long Ideas Technicals Movers Trading Ideas General

     

    Related Articles (CELG)

    View Comments and Join the Discussion!